Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Other Operating Expenses: 2021-2025

Historic Other Operating Expenses for Cidara Therapeutics (CDTX) over the last 1 years, with Sep 2025 value amounting to $45.0 million.

  • Cidara Therapeutics' Other Operating Expenses was N/A to $45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.4 million, marking a year-over-year change of. This contributed to the annual value of $84.9 million for FY2024, which is N/A change from last year.
  • Cidara Therapeutics' Other Operating Expenses amounted to $45.0 million in Q3 2025, which was up 1,243.58% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Other Operating Expenses registered a high of $84.9 million during Q2 2024, and its lowest value of -$88.1 million during Q4 2021.
  • Over the past 2 years, Cidara Therapeutics' median Other Operating Expenses value was $20.5 million (recorded in 2025), while the average stood at $30.1 million.
  • Data for Cidara Therapeutics' Other Operating Expenses shows a maximum YoY crashed of 104.64% (in 2025) over the last 5 years.
  • Over the past 3 years, Cidara Therapeutics' Other Operating Expenses (Quarterly) stood at -$88.1 million in 2021, then reached $84.9 million in 2024, then slumped by 104.64% to $45.0 million in 2025.
  • Its Other Operating Expenses stands at $45.0 million for Q3 2025, versus -$3.9 million for Q2 2025 and -$5.5 million for Q1 2025.